CSIMarket
 
Rocket Pharmaceuticals Inc   (RCKT)
Other Ticker:  
 
 
Price: $26.8100 $-0.47 -1.723%
Day's High: $27.77 Week Perf: -2.86 %
Day's Low: $ 26.66 30 Day Perf: -7.23 %
Volume (M): 1,995 52 Wk High: $ 32.53
Volume (M$): $ 53,475 52 Wk Avg: $21.78
Open: $27.03 52 Wk Low: $14.89



 Market Capitalization (Millions $) 2,215
 Shares Outstanding (Millions) 83
 Employees 143
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -253
 Cash Flow (TTM) (Millions $) 29
 Capital Exp. (TTM) (Millions $) 15

Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc. is a NYSDAQ-listed biopharmaceutical company headquartered in New York City, United States of America. The company was previously known as Inotek Pharmaceuticals Corporation but changed its name to Rocket Pharmaceuticals in 2018.

Rocket Pharmaceuticals is focused on the development of innovative gene therapies for rare genetic diseases. The company's pipeline includes a range of gene therapies for hematologic disorders, neurologic disorders, and rare pediatric diseases. The company's lead product candidate is RP-L102, a gene therapy for Fanconi anemia, which is currently in late-stage clinical development.

The company's mission is to provide cures for rare genetic diseases that have no effective treatment options. Rocket Pharmaceuticals aims to develop therapies that offer durable and transformative outcomes for patients, significantly improving their lives and life expectancy. The company's gene therapy platform is built on lentiviral vector technology, which enables the transfer of modified genes into targeted cells, offering the potential to correct genetic mutations.

Rocket Pharmaceuticals leverages the expertise of a team of world-class scientists and researchers with decades of experience in gene therapy development. The company has established partnerships with leading academic institutions, research organizations, and pharmaceutical companies to advance its gene therapy programs.

In addition to its innovative gene therapy development programs, Rocket Pharmaceuticals is committed to advancing patient access to its therapies. The company is focused on building strong relationships with patient advocacy groups, working closely with these organizations to raise awareness of rare genetic diseases and improve patient outcomes.

Overall, Rocket Pharmaceuticals Inc is a leading biopharmaceutical company focused on the development of gene therapies for rare genetic diseases. The company's innovative gene therapy platform and commitment to improving patient outcomes make it a key player in the biotech industry with huge potential to transform the lives of patients around the world.


   Company Address: 9 Cedarbrook Drive Cranbury 8512 NJ
   Company Phone Number: 659-8001   Stock Exchange / Ticker: NASDAQ RCKT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

Rocket Pharmaceuticals Achieves Significant Progress in 2023, Solidifying Position as a Key Player in Rare Genetic Disorder Therapies

Published Mon, Feb 26 2024 9:01 PM UTC

Rocket Pharmaceuticals, a late-stage biotechnology company dedicated to developing innovative genetic therapies for rare disorders, has recently reported its financial and operational results for the fourth quarter and full year ending December 31, 2023. The company reported strong performance and progress across all six disclosed gene therapy programs, solidifying its posit...

Business Update

Delays in FDA Review Pose Challenges for Rocket Pharmaceuticals' Promising Rare Disease Treatment

Published Tue, Feb 13 2024 12:00 PM UTC

Rocket Pharmaceuticals Faces Delays in FDA Review of Promising Rare Disease TreatmentRocket Pharmaceuticals, a leading biotechnology company focused on genetic therapies for rare disorders, recently announced that the U.S. Food and Drug Administration (FDA) has extended its Priority Review period for their Biologics License Application (BLA) for KRESLADI (marnetegragene auto...

Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc. Faces Operating Shortfall Increase in Q3 2023 Earnings Season

Rocket Pharmaceuticals Inc, a leading late-stage biotechnology company, recently reported its financial results for the quarter ending September 30, 2023. Despite not disclosing revenue numbers at this time, investors are closely monitoring the company's operating shortfall, which stood at $-65.429 million during the aforementioned period.
To provide some context, the company had reported an operating shortfall of $-58.488 million in the third quarter of 2022. This indicates a slight increase in the operating shortfall for the current period. Moreover, Rocket Pharmaceuticals Inc experienced a net deficit of $-61.899 million, expanding from the $-57.756 million deficit of the third quarter of 2022.

Business Update

Rocket Pharmaceuticals Rockets Ahead: Transforming Lives with Rare Disease Therapies, Reports Strong Q3 2023 Results.

Published Mon, Nov 6 2023 9:04 PM UTC


Introduction
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has emerged as a formidable player in the biotechnology industry, working relentlessly towards developing genetic therapies for rare disorders with high unmet needs. In its recent quarterly financial report, Rocket Pharmaceuticals showcased remarkable progress in its pipeline developments, business operations,...

Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc Faces Operating Deficit of $-68.757 Million in Q2 2023: A Closer Look at its Impact on the Company's Shares

As an avid reader of the Wall Street Journal, I would like to offer my interpretation of the recent financial results of Rocket Pharmaceuticals Inc and their impact on the company's shares.
Rocket Pharmaceuticals Inc, a rising corporation in the Major Pharmaceutical Preparations industry, recently reported an operating deficit of $-68.757 million for the second quarter of 2023. While the respective revenue has not been disclosed, it is important to compare these results with the company's performance in the second quarter of 2022.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com